SDZ 220-581NMDA glutamate receptor subtype antagonist CAS# 174575-17-8 |
- MDL-29951
Catalog No.:BCC4059
CAS No.:130798-51-5
- Ro 25-6981 Maleate
Catalog No.:BCC4159
CAS No.:1312991-76-6
- Ro 25-6981
Catalog No.:BCC4158
CAS No.:169274-78-6
- SDZ 220-581 hydrochloride
Catalog No.:BCC4157
CAS No.:179411-93-9
- (+)-MK 801
Catalog No.:BCC1288
CAS No.:70449-94-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 174575-17-8 | SDF | Download SDF |
PubChem ID | 128019 | Appearance | Powder |
Formula | C16H17ClNO5P | M.Wt | 369.74 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 8.57 mg/mL (23.18 mM; Need ultrasonic and warming) | ||
Chemical Name | (2S)-2-amino-3-[3-(2-chlorophenyl)-5-(phosphonomethyl)phenyl]propanoic acid | ||
SMILES | C1=CC=C(C(=C1)C2=CC(=CC(=C2)CP(=O)(O)O)CC(C(=O)O)N)Cl | ||
Standard InChIKey | VBRJFXSFCYEZMQ-HNNXBMFYSA-N | ||
Standard InChI | InChI=1S/C16H17ClNO5P/c17-14-4-2-1-3-13(14)12-6-10(8-15(18)16(19)20)5-11(7-12)9-24(21,22)23/h1-7,15H,8-9,18H2,(H,19,20)(H2,21,22,23)/t15-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Competitive NMDA receptor antagonist (pKi = 7.7). Centrally active following oral administration (ED50 < 3.2 mg/kg for protection against MES-induced seizures). |
SDZ 220-581 Dilution Calculator
SDZ 220-581 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7046 mL | 13.523 mL | 27.046 mL | 54.0921 mL | 67.6151 mL |
5 mM | 0.5409 mL | 2.7046 mL | 5.4092 mL | 10.8184 mL | 13.523 mL |
10 mM | 0.2705 mL | 1.3523 mL | 2.7046 mL | 5.4092 mL | 6.7615 mL |
50 mM | 0.0541 mL | 0.2705 mL | 0.5409 mL | 1.0818 mL | 1.3523 mL |
100 mM | 0.027 mL | 0.1352 mL | 0.2705 mL | 0.5409 mL | 0.6762 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Description: IC50 Value: N/A SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid) is a potent, competitive antagonist at the NMDA glutamate receptor subtype. in vitro: Wake-promoting doses of LSN2463359 and LSN2814617 attenuated deficits in performance induced by the competitiveNMDA receptor antagonist SDZ 220,581 in two tests of operant behaviour: the variable interval 30 s task and the DMTP task [1]. in vivo: Administration of SDZ 220-581 or CGS 19755 was associated with a robust reduction in PPI, whereas L-701,324, 4-Cl-KYN or MLA failed to alter PPI [2]. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action [3]. Rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude [4]. Clinical trial: N/A
- 2-Allylphenol
Catalog No.:BCC8518
CAS No.:1745-81-9
- alpha-Spinasterol glucoside
Catalog No.:BCN1120
CAS No.:1745-36-4
- Tipranavir
Catalog No.:BCC2002
CAS No.:174484-41-4
- Sanggenol A
Catalog No.:BCN3602
CAS No.:174423-30-4
- Amiloride HCl dihydrate
Catalog No.:BCC5068
CAS No.:17440-83-4
- Riluzole
Catalog No.:BCC3849
CAS No.:1744-22-5
- Tsugaric acid A
Catalog No.:BCN2980
CAS No.:174391-64-1
- Picropodophyllotoxin
Catalog No.:BCN2585
CAS No.:17434-18-3
- Astragaloside
Catalog No.:BCN5959
CAS No.:17429-69-5
- Caohuoside E
Catalog No.:BCN8198
CAS No.:174286-23-8
- Epimedin K
Catalog No.:BCN8201
CAS No.:174286-13-6
- Apigenin 7-O-(2G-rhamnosyl)gentiobioside
Catalog No.:BCN1524
CAS No.:174284-20-9
- SDZ 220-040
Catalog No.:BCC6992
CAS No.:174575-40-7
- SB 218795
Catalog No.:BCC7037
CAS No.:174635-53-1
- SB-222200
Catalog No.:BCC1926
CAS No.:174635-69-9
- Talnetant
Catalog No.:BCC1981
CAS No.:174636-32-9
- Phalloidin
Catalog No.:BCC7945
CAS No.:17466-45-4
- AN-2690
Catalog No.:BCC1360
CAS No.:174671-46-6
- CH 275
Catalog No.:BCC5913
CAS No.:174688-78-9
- 2-Amino-6-methoxybenzothiazole
Catalog No.:BCC8542
CAS No.:1747-60-0
- Ginsenoside Rh4
Catalog No.:BCN3503
CAS No.:174721-08-5
- Carabrone
Catalog No.:BCN1121
CAS No.:1748-81-8
- Fmoc-Hyp(Bzl)-OH
Catalog No.:BCC3255
CAS No.:174800-02-3
- 3-Amino-4-methoxybenzamide
Catalog No.:BCC8612
CAS No.:17481-27-5
The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.[Pubmed:8957251]
Eur J Pharmacol. 1996 Oct 31;314(3):307-11.
The present studies investigated whether SDZ 220-581 ((S)-alpha-amino 2'chloro-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid), a potent, competitive antagonist at the NMDA glutamate receptor subtype, reversed haloperidol-induced catalepsy in rats, a widely used model of Parkinson's disease. SDZ 220-581 (0.32-3.2 mg/kg i.p.) dose- and time-dependently reduced the time spent in an abnormal position induced by haloperidol (1.0 mg/kg s.c.). Compared to other NMDA receptor antagonists the rank order of potency was MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine) > SDZ 220-581 > SDZ EAA 494 (D-CPPene: (S)-(E)-4-(3-phosphonoprop-2-enyl)-piperazine-2-carboxylic acid) > SDZ EAB 515 ((S)-alpha-amino-5-(phosphonomethyl)[1,1'-biphenyl]-3-propanoic acid). Since it has been demonstrate that SDZ 220-581 counters the effects of L-dihydroxyphenylalanine (L-DOPA) on the motor disturbances of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-pre-treated primates, the results suggest that the reversal of haloperidol-induced catalepsy by competitive NMDA receptor antagonists may not be predictive of efficacy in other models of Parkinson's disease.
Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats.[Pubmed:9918570]
J Pharmacol Exp Ther. 1999 Feb;288(2):643-52.
Noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists such as phencyclidine are psychotomimetics and disrupt prepulse inhibition (PPI), a measure of sensorimotor gating that is deficient in schizophrenia. Systemically administered competitive NMDA receptor antagonists do not disrupt PPI in rats, leading to speculation that these compounds might have use as neuroprotective agents without the risk of psychotomimetic side effects. The effects on sensorimotor gating and locomotor activity of competitive NMDA receptor antagonists that either penetrate (SDZ 220-581 and SDZ EAB-515) or poorly penetrate [SDZ EAA-494 (D-CPPene)] the blood-brain barrier were compared. Rats were treated with either SDZ 220-581 (0, 2.5, or 5.0 mg/kg) or SDZ EAB-515 (0, 3.0, 10.0, or 30.0 mg/kg) and tested for PPI and locomotor activity. Different rats were tested for PPI after either systemic (0, 0.5, 1.0, or 5.0 mg/kg) or intra-amygdala (0 or 1.0 microg/microl) administration of D-CPPene. Finally, rats were pretreated with clozapine (0 or 5.0 mg/kg) or haloperidol (0 or 0.1 mg/kg), together with SDZ 220-581 (0 or 2.5 mg/kg), and tested. SDZ 220-581 and SDZ EAB-515 decreased PPI without affecting startle magnitude. Reduced PPI was noted after central but not systemic administration of D-CPPene. The gating deficits produced by SDZ 220-581 were blocked by clozapine or haloperidol. Movement pattern analysis indicated that locomotor activity was increased by SDZ 220-581 and SDZ EAB-515 in a phencyclidine-like manner. These results indicate that competitive NMDA receptor antagonists, if they gain sufficient access to the brain, produce a behavioral profile that resembles that of the psychotomimetic noncompetitive antagonists.
Biphenyl-derivatives of 2-amino-7-phosphonoheptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonist--I. Pharmacological characterization in vitro.[Pubmed:8887974]
Neuropharmacology. 1996 Jun;35(6):643-54.
Omega-Phosphono-substituted alpha-amino acids have long been known to be antagonists at the N-methyl-D-aspartate (NMDA) receptor. D-2-Amino-5-phosphonopentanoic (D-AP5) and D-2-amino-7-phosphonoheptanoic (D-AP7) acids are the "prototype" compounds of this kind. Insertion of a biphenyl-moiety in the middle of the AP7 chain results in increased affinity and reverses the enantioselectivity from a D- to an L-form preference (Muller et al., (1992) Helv. Chim. Acta 75: 855-864). We describe here a series of substituted biphenyl-AP7-derivatives, the most potent of which have affinities (in a [3H]CGP-39653 binding assay using native and recombinant receptors) and potencies (antagonism of NMDA-induced depolarizations in a cortical wedge preparation; inhibition of glutamate-stimulated [3H]MK-801 binding under non-equilibrium conditions) in the low nanomolar range. Structure-activity relationships show that hydroxy-substitution at the C5-atom in the AP7-chain as well as substitution in the second phenyl ring with space filling (such as chloro-)groups in the para- and especially the ortho-position (extending the torsion angle of the two rings) increase affinity and potency of these compounds. They have no relevant affinities for the strychnine-insensitive glycine co-agonist site or the MK-801/PCP channel blocking site on the NMDA receptor complex. AMPA- and kainate-induced responses were not affected by biphenyl-analogues. These compounds also do not interact with a number of other neurotransmitter receptor sites, and they do not inhibit the uptake of [3H] glutamate in rat brain synaptosomes. However, they display affinities in the (sub)micromolar range for a non-NMDA, non-AMPA, non-kainate binding site for [3H]glutamate, measured in the presence of calcium chloride, the functional correlate of which has not yet been elucidated.
Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo.[Pubmed:8887975]
Neuropharmacology. 1996 Jun;35(6):655-69.
A selection of biphenyl-analogues of 2-amino-7-phosphonoheptanoic acid (AP7), N-methyl-D-aspartate (NMDA) receptor antagonists with high affinity in vivo efficacy. The lead compound SDZ EAB 515 was found to inhibit L-phenylalanine uptake by the large neutral amino acid carrier in vitro and in vivo; active transport may thus confer a good bioavailability to this class of compounds. CNS effects were demonstrated by significant changes in 2-deoxyglucose-uptake in various brain regions at doses from 1 to 10 mg/kg i.p. With the most active agent, SDZ 220-581, full protection against maximal electroshock seizures (MES) was obtained at oral doses of 10 mg/kg in rats and in mice. The compound had a fast onset (< or = 1 hr) and a long duration (> or = 24 hr) of action. Motor-debilitating effects (impairment of rotarod performance) occurred at doses about 10 times higher than those required for protection against MES. Neuroprotective activity was demonstrated by the ability of the compounds to reduce the extent of quinolinic acid-induced striatal lesions in rats, in the dose range of 3-15 mg/kg (i.p.) or 10-50 mg/kg (p.o.). In the middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats, the test compounds reduced the infarct size by 40-50% when given i.v. before or by 20-30% when given i.v. 1 hr after MCAO. SDZ 220-581 provided 20-30% protection at > or = 2 x 10 mg/kg p.o. This compound also showed analgesic activity at low oral doses in a model of neuropathic pain, although higher doses were required in model of mechanical inflammatory hyperalgesia. Unexpectedly, SDZ 220-581 at low s.c. doses counteracted the antiparkinsonian effects of L-DOPA in MPTP-treated marmosets. (Sub)chronic administration of SDZ 220-581 did not reduce its ability to protect against quinolinic acid neurotoxicity, and no upregulation of NMDA receptors was detected using a [3H]CGP-39653 binding assay. In conclusion, from a series of biphenyl-AP7-derivatives, SDZ 220-581 is clearly the most active compound in vivo. Its pharmacological profile with a good, long-lasting oral activity might open up novel therapeutic applications for competitive NMDA receptor antagonists.